Hibercell
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
619 W 54th St Fl 8, New York City, New Y...Phone Number
(651) 675-0300Website
www.hibercell.comRevenue
$11.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Hibercell
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes. The company is led by a team of experienced biotech executives committed to combining traditional drug development with computational expertise. HiberCell's mission is to improve the lives of cancer patients by pioneering new treatment paradigms.Explore more
Hibercell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hibercell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Hibercell has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Hibercell launches new products
Earning: See what the market has to say on Hibercell recently announced quarterly report
Hibercell, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Hibercell has new funding data
Click to see if Hibercell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Hibercell
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Hibercell is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Hibercell as Masked Content
Find more new buyers
Compare Similar Companies to Hibercell
Compare insights from companies similar to Hibercell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
1997
JA
Joseph AttawayChief Financial Officer & Shareholder & Partner & Co-Founder
Company Profile Activity
Activity Insights
Hibercell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hibercell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hibercell.
Hibercell financials insights
Gather financial insights about Hibercell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$60.8M
2021
Series B
$67.4M
Debt
$30M
Hibercell Tech Stack
A closer look at the technologies used by Hibercell
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Left Company
Executive Move
Project
A mid-level source in Financial Planning has indicated that the organization has completed initiatives related to board reporting within the last nine months.
Financial Planning, Board of Directors
Project
A mid-level source in Financial Planning has indicated that the organization has completed initiatives related to budget creation and management within the last nine months.
Financial Planning
Project
Financial Planning, Forecasting
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Hibercell
Sign Up For FreeTo access detailed company insights
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes... Read More
